» Articles » PMID: 26113758

Light Dosimetry of Interstitial PDT of Human Prostate

Overview
Date 2015 Jun 27
PMID 26113758
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We report results of in-vivo light dosimetry of light fluence (rate) in human prostate during photodynamic therapy (PDT). Measurements were made in-vivo at the treatment wavelength (732nm) in 15 patients in three to four quadrants using isotropic detectors placed inside catheters inserted into the prostate. The catheter positions are determined using a transrectal ultrasound (TRUS) unit attached to a rigid template with 0.5-cm resolution. Cylindrical diffusing fibers with various lengths are introduced into the catheters to cover the entire prostate gland. For the last four patients, distributions of light fluence rate along catheters were also measured using a computer controlled step motor system to move multiple detectors to different distances (with 0.1 mm resolution). To predict the light fluence rate distribution, a kernel-based model was used to calculate light fluence rate using either (a) the mean optical properties (assuming homogeneous optical properties) for all patients or (b) using distributions of optical properties measured for latter patients. Standard deviations observed between the calculations and measurements were 56% and 34% for (a) and (b), respectively. The study shows that due to heterogeneity of optical properties significant variations of light fluence rate were observed both intra and inter prostates. However, if one assume a mean optical properties (μ = 0.3 cm, μ' = 14 cm), one can predict the light fluence rate to within a maximum error 200% for 80% of the cases and a mean error of 105%. To improve the prediction of light fluence rate further would require determination of distribution of optical properties.

Citing Articles

Integrated light dosimetry system for prostate photodynamic therapy.

Li J, Zhu T, Zhou X, Andreea D, Finlay J Proc SPIE Int Soc Opt Eng. 2015; 6845.

PMID: 26113761 PMC: 4477956. DOI: 10.1117/12.763806.


Modeling light fluence rate distribution in optically heterogeneous prostate photodynamic therapy using a kernel method.

Li J, Zhu T Proc SPIE Int Soc Opt Eng. 2015; 6427.

PMID: 26113759 PMC: 4477975. DOI: 10.1117/12.702798.


Prostate PDT dosimetry.

Zhu T, Finlay J Photodiagnosis Photodyn Ther. 2014; 3(4):234-46.

PMID: 25046988 PMC: 4469490. DOI: 10.1016/j.pdpdt.2006.08.002.


A review of in-vivo optical properties of human tissues and its impact on PDT.

Sandell J, Zhu T J Biophotonics. 2011; 4(11-12):773-87.

PMID: 22167862 PMC: 3321368. DOI: 10.1002/jbio.201100062.


The role of photodynamic therapy (PDT) physics.

Zhu T, Finlay J Med Phys. 2008; 35(7):3127-36.

PMID: 18697538 PMC: 2673560. DOI: 10.1118/1.2937440.

References
1.
Chang S, Buonaccorsi G, MacRobert A, Bown S . Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate. 1997; 32(2):89-98. DOI: 10.1002/(sici)1097-0045(19970701)32:2<89::aid-pros3>3.0.co;2-a. View

2.
Zhu T, Dimofte A, Finlay J, Glatstein E, Hahn S . Detector Calibration factor for interstitial light dosimetry using isotropic detectors with scattering tip. Proc SPIE Int Soc Opt Eng. 2015; 5689. PMC: 4477970. DOI: 10.1117/12.590330. View

3.
Zhu T, Finlay J, Hahn S . Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B. 2005; 79(3):231-41. PMC: 4470428. DOI: 10.1016/j.jphotobiol.2004.09.013. View

4.
Verigos K, Stripp D, Mick R, Zhu T, Whittington R, Smith D . Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol. 2006; 25(1-2):373-87. DOI: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.230. View

5.
Hsi R, Kapatkin A, Strandberg J, Zhu T, Vulcan T, Solonenko M . Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res. 2001; 7(3):651-60. View